- Home
- BANX vs SLN Comparison
BANX vs SLN Comparison
Compare BANX & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- SLN
- Stock Information
- Founded
- BANX 2013
- SLN 1994
- Country
- BANX United States
- SLN United Kingdom
- Employees
- BANX N/A
- SLN N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- BANX Finance
- SLN Health Care
- Exchange
- BANX Nasdaq
- SLN Nasdaq
- Market Cap
- BANX 144.3M
- SLN 165.3M
- IPO Year
- BANX N/A
- SLN N/A
- Fundamental
- Price
- BANX $20.05
- SLN $5.84
- Analyst Decision
- BANX
- SLN Buy
- Analyst Count
- BANX 0
- SLN 5
- Target Price
- BANX N/A
- SLN $32.60
- AVG Volume (30 Days)
- BANX 16.5K
- SLN 189.3K
- Earning Date
- BANX 07-15-2025
- SLN 05-08-2025
- Dividend Yield
- BANX 10.45%
- SLN N/A
- EPS Growth
- BANX N/A
- SLN N/A
- EPS
- BANX 2.35
- SLN N/A
- Revenue
- BANX $29,467,794.00
- SLN $27,701,000.00
- Revenue This Year
- BANX N/A
- SLN N/A
- Revenue Next Year
- BANX N/A
- SLN N/A
- P/E Ratio
- BANX $8.53
- SLN N/A
- Revenue Growth
- BANX 2.73
- SLN N/A
- 52 Week Low
- BANX $17.91
- SLN $1.97
- 52 Week High
- BANX $21.67
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- BANX 47.33
- SLN 74.79
- Support Level
- BANX $19.85
- SLN $4.69
- Resistance Level
- BANX $20.56
- SLN $5.37
- Average True Range (ATR)
- BANX 0.44
- SLN 0.48
- MACD
- BANX -0.03
- SLN 0.13
- Stochastic Oscillator
- BANX 24.39
- SLN 89.59
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.